Lumos Pharma, Inc.
LUMO · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 48.8% | 195.8% | -80% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 99.6% | 98.8% | 97.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,052.3% | -1,602.7% | -6,581.8% | -1,209% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,028.5% | -1,547.3% | -6,327.9% | -1,144.9% |
| EPS Diluted | -0.9 | -0.93 | -1.29 | -1.17 |
| % Growth | 3.2% | 27.9% | -10.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |